9B06

9B06 is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by 9Bio Therapeutics for the treatment of advanced and metastatic solid tumors. The molecule is designed to conditionally target Programmed Death-Ligand 1 (PD-L1) and an undisclosed complementary tumor-associated antigen (TAA) that is highly expressed in aggressive and metastatic cancers. By utilizing a conditional binding approach for the PD-L1 arm, 9B06 aims to localize the delivery of its cytotoxic payload to the tumor microenvironment, potentially improving the therapeutic index compared to traditional ADCs or checkpoint inhibitors. The specific payload and linker chemistry have not been publicly disclosed.